Drug intelligence / Profile preview

PTS-201

Development stage: Preclinical
Lead developer: METiS Therapeutics

Overview

PTS-201 is a biologic drug candidate being developed by Metis Pharmaceuticals for veterinary applications, specifically targeting severe limb ischemia and tissue necrosis. Currently in the preclinical stage of development, PTS-201 is part of the company's specialized animal health pipeline. While the specific molecular target and mechanism of action have not been publicly disclosed, the program aims to address critical vascular conditions in animals that lead to restricted blood supply and subsequent tissue death. The development of PTS-201 leverages Metis Pharmaceuticals' expertise in advanced delivery systems and therapeutic biologics to provide new treatment options for ischemic diseases in the veterinary sector.

Beyond the preview

Go deeper on PTS-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTS-201.

Explore the full profile